All In Biotech

Drug Trial Radar · NCT07807995

A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy

A Phase 3, Single-Arm, Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy

Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

605

Planned (sponsor's estimate)

Start

Sep 17, 2026

Primary completion

Dec 28, 2029

Study completion Dec 28, 2029

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
Sep 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of povetacicept in participants with immunoglobulin A nephropathy (IgAN).

Conditions

  • Immunoglobulin A Nephropathy

Interventions

  • PovetaciceptDrug

    Subcutaneous injection administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Day 1 up to Week 112

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Western Nephrology - Arvada

    Arvada, Colorado

  • CTR Oakwater, LLC

    Orlando, Florida

  • Idaho Kidney Institute- Idaho Falls

    Idaho Falls, Idaho

  • Prolato Clinical Research Center - Kirby Dr

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.